Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Paratek Pharmaceuticals (PRTK) Stock Price

Media stories about Paratek Pharmaceuticals (NASDAQ:PRTK) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.1321713125051 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded down $0.10 during midday trading on Wednesday, hitting $17.75. The stock had a trading volume of 294,100 shares, compared to its average volume of 311,060. Paratek Pharmaceuticals has a 52 week low of $13.95 and a 52 week high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $495.95, a price-to-earnings ratio of -4.76 and a beta of 0.70.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative return on equity of 100.84% and a negative net margin of 1,236.38%. analysts anticipate that Paratek Pharmaceuticals will post -3.32 EPS for the current year.

Several brokerages have recently weighed in on PRTK. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price target on shares of Paratek Pharmaceuticals in a research report on Thursday, September 21st. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Wednesday, January 10th. Robert W. Baird reiterated a “buy” rating and set a $40.00 price target on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. ValuEngine cut Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 29th. Finally, Guggenheim assumed coverage on Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They set a “buy” rating and a $44.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $40.00.

ILLEGAL ACTIVITY WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3142735/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-paratek-pharmaceuticals-prtk-stock-price.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.